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Abstract Oxidative stress is a major contributing factor in
a range of brain pathologies and in the etiology of depression.
1-Methyl-1,2,3,4-tetrahydroisoquinoline (1MeTIQ) is an
endogenous substance which is present in the mammalian
brain and exhibits neuroprotective, and monoamine oxidase
(MAO)-inhibiting properties. In the present study, in order to
investigate the potential role of 1MeTIQ as an antidepres-
sant, we tested antidepressant-like effects of 1MeTIQ in
comparison with desipramine (a classic antidepressant) in
the forced swimming test (FST), and using HPLC method-
ology, we measured the concentrations of monoamines
(dopamine, noradrenaline, serotonin) and the rate of their
metabolism. 1MeTIQ given alone as well as in combination
with desipramine produced an antidepressant-like effect and
decreased the immobility time in the FST. Neurochemical
data have shown that 1MeTIQ like desipramine, activated
the noradrenergic system. However, the mechanism of
action of 1MeTIQ is broader than the actions of desipramine,
and 1MeTIQ inhibits the MAO-dependent oxidation of
dopamine and serotonin in all investigated structures. We
can conclude that 1MeTIQ exhibits antidepressant-like
activity in the FST in the rat. The mechanism of its antide-
pressant action differs from desipramine and seems to be
mostly associated with the inhibition of the catabolism of
monoamines and their increased concentrations in the brain.
1MeTIQ seems to be very beneficial from the clinical point
of view as a reversible MAO inhibitor with a significant
antidepressant effects.
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Introduction
One of the popular theories states that depression is caused
by the depletion of monoaminergic activity (especially
noradrenergic and/or serotoninergic). Additionally, different
studies have suggested the role of dopamine in the patho-
genesis of depression (Brown and Gershon 1993). There is a
biochemical evidence indicating that dopaminergic system
plays a role in the antidepressant-like effect in the forced
swimming test (FST) (Renard et al. 2003). Desipramine is a
classic tricyclic antidepressant (TCA) with a substantial
selectivity for noradrenaline reuptake (Wroblewski et al.
1996) and via this mechanism it elevates the noradrenaline
concentration. Desipramine has been studied extensively in
behavioral models of depression in rodents (Antonio et al.
1988; Detke et al. 1995, 1997; Detke and Lucki 1996).
Recent studies have suggested that oxidative stress may be
involved in etiopathology of a variety of diseases, such as
depression, anxiety, or cognitive dysfunctions (Bhattacharya
and Muruganandam 2003). Preclinical and clinical experi-
ments indicated that stress and depression led to reduction in
the number of the adult hippocampal neurons (Tsankova
et al. 2006). Some authors demonstrated that chronic expo-
sure to stressful constraints in rodents produced depressive
behavior (Berton et al. 2006; Kim and Han 2006; Covington
et al. 2009; Kim et al. 2012). There is evidence that neuro-
protective compounds possess antidepressant-like properties
(Scapagnini et al. 2012). 1-Methyl-1,2,3,4-tetrahydroiso-
quinoline (1MeTIQ) is an endogenous compound showing
neuroprotective (Antkiewicz-Michaluk et al. 2001, 2006)
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and antiaddictive (Wa˛sik et al. 2007) properties present in the
mammalian brain (Yamakawa et al. 1999. Our earlier studies
demonstrated that 1MeTIQ inhibited both monoamine oxi-
dase A (MAO-A) and B (MAO-B) enzymatic activities and
increased monoamine neurotransmitter levels in the brain
(Patsenka and Antkiewicz-Michaluk 2004). 1MeTIQ
inhibits the formation of 3,4-dihydroxyphenylacetic acid
(DOPAC), lowers the production of free radicals and shifts
dopamine catabolism toward the catechol-O-methyltrans-
ferase (COMT)-dependent O-methylation, and such mech-
anism of action seems to be important for its neuroprotective
activity (Antkiewicz-Michaluk et al. 2001). The constant
presence of 1MeTIQ in the mammalian brain suggests that
1MeTIQ may play a crucial physiological role as an
endogenous regulator of dopaminergic activity (Vetulani
et al. 2003). Additionally, as we showed earlier, 1MeTIQ
administered systemically to rats produced a dose-dependent
antidepressant-like effect in the forced swimming test (FST)
(Wa˛sik et al. 2013). Monoamine oxidase inhibitors (MAOIs)
are classic drugs in the treatment of depression. Already in
the 1970s preclinical investigations demonstrated that MA-
OIs showed antidepressant-like properties (Porsolt et al.
1978). The FST described originally by Porsolt et al. (1977)
is the most common test used for evaluation of antidepres-
sant-like effects of different drugs. A relative rapidity in
testing of antidepressant action and sensitivity to short-term
antidepressant effects are the major advantages of the FST in
drug discovery.
The aim of the present study was to investigate the
antidepressant properties of 1MeTIQ given in a low dose
alone and in combination with the classical antidepres-
sant, desipramine in the FST. What is more, in the bio-
chemical studies the rate of monoamine (dopamine,
noradrenaline, and serotonin) metabolism was estimated
in some rat brain structures. Additionally, in order to
exclude the psychostimulating activity of 1MeTIQ, the
locomotor activity of rats after administration of the
investigated drugs was measured in actometers (Opto-




Behavioral tests were carried out on male Wistar rats of
initial body weight 220–240 g (about 7 weeks old) kept
under standard laboratory conditions, 6–8 to a large animal
cage. All animals had free access to standard laboratory
food and tap water and were maintained at room temper-
ature (22 C) under an artificial light/dark cycle (12/12 h,
light on from 7 a.m.).
The rats were administered desipramine at a dose of
10 mg/kg intraperitoneally (i.p.) once 1 h before the forced
swim test. 1MeTIQ in a dose of 10 mg/kg i.p. was
administered once 15 min before desipramine injection.
Control rats were treated with an appropriate solvent.
Immediately after the end of behavioral experiments, the
rats were killed by decapitation and different structures of
the brain were dissected. The experiments were carried out
between 9.00 and 16.00 h.
All procedures were carried out in accordance with the
National Institutes of Health Guide for the Care and Use of
Laboratory Animals and were granted an approval from the
Bioethics Commission as compliant with Polish Law. All
the experimental procedures were approved by the Local
Bioethics Commission of the Institute of Pharmacology,
Polish Academy of Sciences in Krako´w.
Drugs
1-Methyl-1,2,3,4-tetrahydroisoquinoline (1MeTIQ) was
synthesized by Dr. Jan Boksa, (Department of Drug
Chemistry, Institute of Pharmacology, Polish Academy of
Sciences, Krakow, Poland). Purity of the compound was
verified by measurement of the melting point, and homo-
geneity was assessed on a chromatographic column.
Desipramine (Sigma-Aldrich, USA) and 1MeTIQ were
dissolved in sterile 0.9 % NaCl solution and injected in a
volume of 1 ml/kg.
Behavioral Tests
Forced Swimming Test
The studies were carried out according to the method of
Porsolt et al. (1978). The rats were placed in non-trans-
parent plastic cylinders (height 50 cm, diameter 23 cm)
containing 30 cm of water, maintained at 25 C. Two swim
sessions were conducted: an initial 15-min pretest followed
24 h later by a 5-min test. After both sessions, rats were
removed from cylinders and returned to their home cages.
Behavioral observations were performed according to
Detke et al. (1995) and during the 5-min test session three
different behaviors were recorded: immobility—when rats
remained floating passively in the water; swimming—if
they were making active swimming movements; climb-
ing—when they were making active attempts in and out of
the water with their forepaws, usually directed against the
walls.
Locomotor Activity
The locomotor activity was examined in actometers (Opto-
Varimex activity monitors, Columbus Inst., USA) linked
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on-line to an IBM-PC compatible computer. Each cage
(43 9 44 9 25 cm) was surrounded with a 15 9 15 array
of photocell beams located 3 cm above the floor surface as
reported previously (Filip et al. 2007). Interruptions of
these photocell beams were counted as a measure of hor-
izontal locomotor activity defined as the distance traveled
(in cm). Horizontal locomotor activity was recorded for
90 min and analyzed using Auto-Track Software Program
(Columbus Instruments, USA). The rats received desipra-
mine in a dose of 10 mg/kg i.p. acutely; 1MeTIQ was
administered in a dose of 10 mg/kg i.p. also acutely. In the
combination group, 1MeTIQ was given 15 min before
desipramine administration. The control group was treated
with saline. The animals were transferred to the experi-
mental cages 15 min after desipramine injections. Hori-
zontal locomotor activity was assessed for 90 min. Seven
animals per group were used.
Biochemical Assays
After the end of the behavioral experiments, the rats were
killed by decapitation and the hypothalamus and striatum
were dissected immediately and the obtained tissue was
frozen on solid CO2 (-70 C) and stored until used for
biochemical assay. Dopamine and its metabolites, 3,4-
dihydroxyphenylacetic acid (DOPAC), 3-methoxytyramine
(3-MT) and final metabolite, homovanillic acid (HVA);
serotonin (5-HT) and its metabolite 5-hydroxyindoleacetic
acid (5-HIAA); noradrenaline and its metabolite 3-metoxy-
4-hydroxyphenylglycol (NMN) were assayed by means of
high-performance liquid chromatography (HPLC) with
electrochemical detection. The chromatograph HP 1050;
Hewlett-Packard, Golden, CO, USA was equipped with
C18 columns. The tissue samples were weighed and
homogenized in ice-cold 0.1 M perchloroacetic acid con-
taining 0.05 mM ascorbic acid. After centrifugation
(10,0009g, 5 min), the supernatants were filtered through
RC 58 0.2-im cellulose membranes (Bioanalytical Sys-
tems, West Lafayette, IN, USA). The mobile phase con-
sisted of 0.05 M citrate–phosphate buffer, pH 3.5, 0.1 mM
EDTA, 1 mM sodium octyl sulfonate, and 3.5 % methanol.
The flow rate was maintained at 1 ml/min. Dopamine,
serotonin, noradrenaline and its metabolites were quanti-
fied by peak height comparison with standards run on the
day of analysis.
Statistical Analysis
The results of behavioral (FST) test was measured by
means of a one-way analysis of variance (ANOVA) and
neurochemical tests were analyzed by means of a two-way
analysis of variance (ANOVA) followed when appropriate,
by Duncan’s post hoc test. The results were considered
statistically significant when P \ 0.05. The data from
locomotor activity test were analyzed by means of a two-
way analysis of variance (ANOVA) for repeated measures,
followed when appropriate, by Duncan’s post hoc test. The
results were considered statistically significant when
P \ 0.05.
Results
The Effect of 1MeTIQ, Desipramine, and Their
Combined Administration on Performances of Rats
in the Forced Swimming Test
Acute administration of both doses of desipramine (10 and
20 mg/kg i.p.) or 1MeTIQ (10 mg/kg i.p.) produced a
significant decrease in the immobility time in the FST
(F[4,22] = 8.93, P \ 0.01) (Fig. 1a). The one-way ANOVA
indicated also a significant reduction of the immobility time
in the combination group, when 1MeTIQ (10 mg/kg i.p.) was
combined with desipramine (10 mg/kg i.p.) (Fig. 1a) with
simultaneous prolongation of the swimming time (P \ 0.05)
(Fig. 1b). The statistical analysis revealed a significant
increase in the climbing activity after systemic administra-
tion of 1MeTIQ and desipramine in a higher dose of 20 mg/
kg (F[4,22] = 3.36, P \ 0.05) with no effect of desipramine
in a dose of 10 mg/kg i.p. (Fig. 1c).
The Effect of 1MeTIQ, Desipramine, and Their
Combined Administration on the Locomotor Activity
in Rats
Figure 2 shows that acute administration of 1MeTIQ
(10 mg/kg i.p.) or desipramine (10 mg/kg i.p.) produced a
significant decrease in locomotor activity of rats (P \
0.01). Joint administration of 1MeTIQ and desipramine
produced a stronger decrease in locomotor activity of rats.
The two-way ANOVA for repeated measures demonstrated
no effect of 1MeTIQ (10 mg/kg i.p.) (F[1,24] = 0.5, N.S.)
or desipramine (10 mg/kg i.p.) (F[1,24] = 3.78, N.S.).
Also interaction between 1METIQ versus desipramine was
not significant (F[1,24] = 0.4, N.S.). At the same time, the
two-way ANOVA for repeated measures indicated a sig-
nificant effect of TIME (F[5,120] = 114.9, P \ 0.01),
significant effect of interaction of TIME versus 1MeTIQ
(F[5,120] = 9.9, P \ 0.01) and TIME versus desipramine
(F[5,120] = 19.78, P \ 0.01). The statistical analysis
showed no effect of interaction of TIME versus 1MeTIQ
versus desipramine (F[5,120] = 1.98, N.S.).
Neurotox Res (2014) 25:323–334 325
123
Fig. 1 The effect of 1MeTIQ
on desipramine-induced
changes in the forced swimming
test (FST). The rats received a
single injection of saline
(control), desipramine in two
doses (10 and 20 mg/kg i.p.), or
1MeTIQ (10 mg/kg i.p.). In the
mixed group, 1MeTIQ was
given 15 min before
desipramine (10 mg/kg i.p.)
injection. The behavioral test
(FST) was conducted 1 h after
desipramine injection. The rats
were placed into the cylinder for
5 min and during this time was
measured three types of
behavior: immobility (a),
swimming (b), and climbing (c).
The data are mean ± SEM, the
number of animals was n = 6;
* P \ 0.05, ** P \ 0.01
difference from control group
(SAL) with Duncan test
Fig. 2 The influence of 1MeTIQ on desipramine-induced changes on
the rats locomotor activity. The rats received a single injection of
saline (control), desipramine (10 mg/kg i.p.), or 1MeTIQ (10 mg/kg
i.p.). In the mixed group, 1MeTIQ was given 15 min before
desipramine injection and 15 min later were placed into actometers
for 90 min. The data are mean ± SEM, the number of animals was
n = 7; The data were analyzed by means of two-way analysis of
variance (ANOVA) for repeated measures, followed when appropri-
ate, by Duncan’s post hoc test. Statistical significance: * P \ 0.05,
** P \ 0.01 versus control group
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Neurochemical Studies
The Influence of 1MeTIQ, Desipramine, and Their
Combined Administration on the Concentration
of Dopamine and Its Metabolites in the Rat Brain
Structures
In the hypothalamus, a two-way ANOVA revealed a significant
effect (F[1,19] = 24.9, P \0.01) of treatment with 1MeTIQ
on dopamine concentration (Table 1). The same statistical test
demonstrated no effect of desipramine (F[1,19] = 0.62, N.S.)
and no interaction between 1MeTIQ versus desipramine
(F[1,19] = 3.39, N.S.) for the level of dopamine (Table 1). The
post hoc test demonstrated that 1MeTIQ elevated dopamine
concentration as well given alone as combined with desipra-
mine (by about 20 and 40 %, respectively). The two-way
ANOVA indicated a significant effect of 1MeTIQ (F[1,19] =
9.5, P\0.01) but no significant effect of desipramine
(F[1,19] = 0.48, N.S.) on the level of DOPAC. The statistical
analysis showed no effect of 1MeTIQ versus desipramine
interaction (F[1,19] = 3.5, N.S.) in influencing DOPAC con-
centration (Table 1). The post hoc Duncan’s test demonstrated
that 1MeTIQ administration significantly reduced the level of
DOPAC (by about 40 %, P\0.01) in the hypothalamus. The
two-way ANOVA revealed a significant effect of 1MeTIQ
(F[1,19] = 12.1, P \0.01) and no effect of desipramine
(F[1,19] = 4.03, N.S.) on 3-MT concentration in the hypo-
thalamus (Table 1). At the same time, the interaction between
1MeTIQ versus desipramine in influencing the level of 3-MT
also was significant (F[1,19] = 8.3, P \0.01). The post hoc
test showed that 1MeTIQ increased the level of 3-MT by 200 %
(P \0.01). In the hypothalamus, the two-way ANOVA
showed no effect of 1MeTIQ (F[1,19] = 0.01, N.S.) and
no effect of desipramine (F[1,19] = 3.5, N.S.) on HVA con-
centration (Table 1). The same statistical analysis demon-
strated no effect of 1MeTIQ versus desipramine interaction
(F[1,19] = 0.09, N.S.) in modulating the level of HVA
(Table 1).
Table 1 The influence of 1MeTIQ, desipramine, and combined administration on dopamine and its metabolites concentrations in rat brain
structures
Treatment 1 (mg/kg) Treatment 2 (mg/kg) DA (ng/g t) DOPAC (ng/g t) 3-MT (ng/g t) HVA (ng/g t)
Hypothalamus
Saline Saline 456 ± 21 126 ± 10 2 ± 0.4 35 ± 6
Desipramine 10 425 ± 22 101 ± 9 3 ± 0.4 28 ± 3
1MeTIQ 10 Saline 548 ± 43*# 78 ± 12** 6 ± 1.2**## 37 ± 7
Desipramine 10 625 ± 30**## 89 ± 6* 3 ± 0.3 26 ± 3
Effect of 1MeTIQ F(1/19) = 24.9 F(1/19) = 9.5 F(1/19) = 12.1 F(1/19) = 0.01
P \ 0.01 P \ 0.01 P \ 0.01 N.S.
Effect of desipramine F(1/19) = 0.62 F(1/19) = 0.48 F(1/19) = 4.03 F(1/19) = 3.5
N.S. N.S. N.S. N.S.
Effect of interaction
1MeTIQ ? desipramine
F(1/19) = 3.39 F(1/19) = 3.5 F(1/19) = 8.3 F(1/19) = 0.09
N.S. N.S. P \ 0.01 N.S.
Striatum
Saline Saline 11,404 ± 503 1,738 ± 107 306 ± 28 1,016 ± 98
Desipramine 10 12,871 ± 453 1,853 ± 59 368 ± 24 1,094 ± 48
1MeTIQ 10 Saline 11,296 ± 656 1,253 ± 79**## 343 ± 15 1,234 ± 193
Desipramine 10 13,083 ± 443* 1,473 ± 67# 325 ± 17 947 ± 57
Effect of 1MeTIQ F(1/19) = 0.92 F(1/19) = 22.3 F(1/19) = 0.01 F(1/19) = 0.15
N.S. P \ 0.01 N.S. N.S.
Effect of desipramine F(1/19) = 9.26 F(1/19) = 3.5 F(1/19) = 0.74 F(1/19) = 1.26
P \ 0.05 N.S. N.S. N.S.
Effect of interaction F(1/19) = 0.09 F(1/19) = 3.3 F(1/19) = 2.52 F(1/19) = 3.85
1MeTIQ ? desipramine N.S. N.S. N.S. N.S.
1MeTIQ was administered once in a dose 10 mg/kg i.p. Desipramine was administered in acute dose 10 mg/kg i.p. In the mixed group, 1MeTIQ
was given 15 min before desipramine injection. Control group was treated with saline. The rats were decapitated about 1 h after desipramine
administration, immediately after completion of a behavioral test (FST). The results are expressed as the mean ± SEM from 4 to 6 samples. The
indices were calculated using concentrations from individual tissue samples. The concentration of dopamine and its metabolites were measured
in ng/g tissue. The data were analyzed by means of two-way analysis of variance ANOVA, followed when appropriate, by Duncan’s post hoc
test. Statistical significance: * P \ 0.05, ** P \ 0.01 versus Control group; # P \ 0.05, ## P \ 0.01 versus desipramine-treated group
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In the striatum, the two-way ANOVA indicated no
effect of 1MeTIQ (F[1,19] = 0.92, N.S.) on dopamine
concentration but the effect of desipramine (F[1,19] =
9.26, P \ 0.01) was significant (Table 1). The same sta-
tistical test demonstrated no effect of 1MeTIQ versus
desipramine interaction (F[1,19] = 0.09, N.S.) for the
level of dopamine (Table 1). The two-way ANOVA
revealed a significant effect of 1MeTIQ (F[1,19] = 22.3,
P \ 0.01) on the level of DOPAC. The statistical analysis
showed no effect of desipramine (F[1,19] = 3.5, N.S.) or
1MeTIQ versus desipramine interaction (F[1,19] = 3.3,
N.S.) in influencing DOPAC concentration (Table 1). The
post hoc Duncan’s test demonstrated that 1MeTIQ
administration significantly reduced the level of DOPAC
(by about 30 %, P \ 0.01) in the striatum. The two-way
ANOVA showed no effect of treatment with 1MeTIQ
(F[1,19] = 0.01, N.S.) and desipramine (F[1,19] = 0.74,
N.S.) on the level of 3-MT. The same statistical test
demonstrated no effect of 1MeTIQ versus desipramine
interaction (F[1,19] = 2.52, N.S.) for 3-MT concentration
(Table 1). The two-way ANOVA showed no effect of
1MeTIQ(F[1,19] = 0.15, N.S.) and no effect of desipra-
mine (F[1,19] = 1.26, N.S.) on HVA concentration in the
striatum (Table 1). The same statistical analysis demon-
strated no effect of 1MeTIQ versus desipramine interaction
(F[1,19] = 3.85, N.S.) in affecting the level of HVA
(Table 1).
The Effect of 1MeTIQ, Desipramine, and Their Combined
Administration on the Rate of Dopamine Metabolism
in the Rat Hypothalamus
In the hypothalamus, the two-way ANOVA revealed a
significant effect of 1MeTIQ on the rate of dopamine
oxidation pathway measured as the index [DOPAC]/
[DA] 9 100 (F[1,19] = 74.9, P \ 0.01). At the same time,
the effect of desipramine (F[1,19] = 1.77, N.S.) or 1Me-
TIQ versus desipramine interaction (F[1,19] = 2.23, N.S.)
was not significant (Fig. 3a). The Duncan’s post hoc test
indicated that 1MeTIQ (10 mg/kg i.p.) reduced the rate of
dopamine oxidation pathway by about 45 % (P \ 0.01)
(Fig. 3a). The same statistical analysis demonstrated a
significant effect of 1MeTIQ (F[1,19] = 24.7, P \ 0.01)
and desipramine (F[1,19] = 6.83, P \ 0.05) on the reup-
take of dopamine measured as the index [3-MT]/
[DOPAC] 9 100 (Fig. 3b). Also the interaction between
1MeTIQ and desipramine was significant (F[1,19] = 15.4,
P \ 0.01). The post hoc test showed that 1MeTIQ given
alone strongly elevated the dopamine reuptake rate (by
about 350 %, P \ 0.01). The two-way ANOVA indi-
cated no effect of 1MeTIQ (F[1,19] = 3.37, N.S.) or
desipramine (F[1,19] = 4.32, N.S.) on the rate of dopa-
mine catabolism (Fig. 3c). Also the interaction between
1MeTIQ and desipramine was not significant (F[1,19] =
0.46, N.S.).
Fig. 3 The effect of 1MeTIQ compared with desipramine as well as
combined administration of both this drugs on the rate: of dopamine
oxidation expressed as ([DOPAC]/[DA]) 9 100 (a); on the inhibition
of dopamine reuptake expressed as ([3-MT]/[DOPAC]) 9 100 (b);
and final dopamine metabolism expressed as ([HVA]/[DA]) 9 100
(c) in the rat hypothalamus. The rats received a single injection of
saline (control), desipramine (10 mg/kg i.p.) or 1MeTIQ (10 mg/kg
i.p.). In the mixed group, 1MeTIQ was given 15 min before
desipramine injection. The rats were decapitated about 1 h after
desipramine administration, immediately after completion of a
behavioral test (FST). The results are expressed as the mean ± SEM
from 4 to 6 samples. The indices were calculated using concentrations
from individual tissue samples. The data were analyzed by means of
two-way analysis of variance ANOVA, followed when appropriate,
by Duncan’s post hoc test. Statistical significance: * P \ 0.05,
** P \ 0.01 versus control group
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The Influence of 1MeTIQ, Desipramine, and Their
Combined Administration on the Concentration
of Noradrenaline and Its Metabolites in Rat Brain
Structures
In the frontal cortex, the two-way ANOVA revealed a
significant effect of 1MeTIQ on the concentration of nor-
adrenaline (F[1,19] = 13.9, P \ 0.01) (Table 2). The sta-
tistical analysis demonstrated no effect of desipramine
(F[1,19] = 0.04, N.S.) on the level of noradrenaline. At the
same time, the interaction of 1MeTIQ and desipramine was
significant (F[1,19] = 6.2, P \ 0.05) (Table 2). The post
hoc test showed that 1MeTIQ given alone as well as
combined with desipramine produced an increase in the
concentration of noradrenaline (by about 50 and 30 %,
respectively). The two-way ANOVA indicated a significant
effect of 1MeTIQ administration (F[1,19] = 46, P \ 0.01)
on the concentration of NMN in the frontal cortex
(Table 2). At the same time, the effect of desipramine
(F[1,19] = 0.97, N.S.) as well as of the interaction
between 1MeTIQ and desipramine (F[1,19] = 0.01, N.S.)
on the level of NMN were not significant (Table 2). The
Duncan’s post hoc test showed that 1MeTIQ administered
alone as well as combined with desipramine produced an
increase in the concentration of NMN by about 200 %
(P \ 0.01).The two-way ANOVA indicated a significant
effect of treatment with 1MeTIQ (F[1,19] = 6.36,
P \ 0.05) on the level of noradrenaline in the hypothala-
mus (Table 2). The same statistical test showed no effect of
desipramine (F[1,19] = 0.58, N.S.) and no effect of
interaction between 1MeTIQ versus desipramine
(F[1,19] = 0.83, N.S.) in affecting noradrenaline concen-
tration. The Duncan’s post hoc test demonstrated that
1MeTIQ given concomitantly with desipramine elevated
the level of noradrenaline by about 15 % (P \ 0.05)
(Table 2). In the hypothalamus, the two-way ANOVA
revealed a significant effect of 1MeTIQ (F[1,19] = 50,
P \ 0.01) and desipramine (F[1,19] = 32.1, P \ 0.01) on
NMN concentration. At the same time, the interaction
between 1MeTIQ versus desipramine for the level of NMN
was not significant (F[1,19] = 0.73, N.S.) (Table 2). The
post hoc analysis showed that treatment with 1MeTIQ or
desipramine produced elevation of NMN concentration by
about 80 % (P \ 0.01), while in the combination group,
the level of NMN increased by about 250 % (P \ 0.01)
(Table 2).
In the striatum, a two-way ANOVA indicated a signif-
icant effect of 1MeTIQ (F[1,19] = 19.7, P \ 0.01) on the
noradrenaline concentration. In opposite to this, the effect
of desipramine was not significant (F[1,19] = 2.26, N.S.)
(Table 2). The same statistical analysis demonstrated that
the interaction between 1MeTIQ versus desipramine was
significant (F[1,19] = 14.8, P \ 0.01) (Table 2). The
Duncan’s post hoc test showed that 1MeTIQ reduced the
concentration of noradrenaline by about 70 % (P \ 0.01).
A two-way ANOVA revealed a significant effect of
Table 2 The influence of 1MeTIQ, desipramine, and combined
administration on noradrenaline and its metabolite concentration in
rat brain structures
Treatment 1 Treatment 2 NA (ng/g t) NMN (ng/g t)
Frontal cortex
Saline Saline 209 ± 5 10 ± 1
Desipramine 10 247 ± 23 13 ± 2
1MeTIQ10 Saline 298 ± 6**# 30 ± 1**##
Desipramine 10 265 ± 6* 32 ± 4**##
Effect of 1MeTIQ F(1/19) = 13.9 F(1/19) = 46
P \ 0.01 P \ 0.01




F(1/19) = 6.2 F(1/19) = 0.01
P \ 0.05 N.S.
Hypothalamus
Saline Saline 1525 ± 71 18 ± 1
Desipramine 10 1512 ± 85 30 ± 2**
1MeTIQ 10 Saline 1664 ± 64 33 ± 2**
Desipramine 10 1809 ± 81*# 49 ± 3**##
Effect of 1MeTIQ F(1/19) = 6.36 F(1/19) = 50
P \ 0.05 P \ 0.01
Effect of desipramine F(1/19) = 0.58 F(1/19) = 32.1
N.S. P \ 0.01
Effect of interaction
1MeTIQ ? desipramine
F(1/19) = 0.83 F(1/19) = 0.73
N.S. N.S.
Striatum
Saline Saline 41 ± 4 13 ± 1
Desipramine 10 44 ± 7 10 ± 1
1MeTIQ 10 Saline 11 ± 4**## 8 ± 1*
Desipramine 10 57 ± 4 15 ± 1#
Effect of 1MeTIQ F(1/19) = 19.7 F(1/19) = 4.69
P \ 0.01 P \ 0.05




F(1/19) = 14.8 F(1/19) = 18.72
P \ 0.01 P \ 0.01
1MeTIQ was administered once in a dose 10 mg/kg i.p. Desipramine
was administered in acute dose 10 mg/kg i.p. In the mixed group,
1MeTIQ was given 15 min before desipramine injection. Control
group was treated with saline. The rats were decapitated about 1 h
after desipramine administration, immediately after completion of a
behavioral test (FST). The results are expressed as the mean ± SEM
from 4 to 6 samples. The indices were calculated using concentrations
from individual tissue samples. The concentration of noradrenaline
and its metabolite was measured in ng/g tissue. The data were ana-
lyzed by means of two-way analysis of variance ANOVA, followed
when appropriate, by Duncan’s post hoc test. Statistical significance:
* P \ 0.05, ** P \ 0.01 versus Control group; # P \ 0.05,
## P \ 0.01 versus desipramine-treated group
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1MeTIQ(F[1,19] = 4.69, P \ 0.05) on NMN concentra-
tion in the rat striatum (Table 2). At the same time, the
effect of desipramine was not significant (F[1,19] = 0.04,
N.S.) but the interaction between 1MeTIQ versus desi-
pramine was significant (F[1,19] = 18.72, P \ 0.01) in
respect of the level of NMN (Table 2).
The Effect of 1MeTIQ, Desipramine, and Their Combined
Administration on the Rate of Noradrenaline Metabolism
in the Rat Hypothalamus
In the hypothalamus, the two-way ANOVA revealed a
significant effect of 1MeTIQ (F[1,19] = 38.5, P \ 0.01)
and desipramine (F[1,19] = 36.1, P \ 0.01) on the rate of
noradrenaline metabolism measured as the index [NMN]/
[NA] (Fig. 4). In contrast to this, the interaction between
1MeTIQ versus desipramine was not significant (F[1,19] =
0.02, N.S.). The post hoc test showed that 1MeTIQ and
desipramine given alone increased the rate of noradrenaline
metabolism by about 80 %, but if both drugs were given in
combination, the elevation was even stronger (by about
180 %) (Fig. 4).
The Influence of 1MeTIQ, Desipramine, and Their
Combined Administration on the Concentration
of Serotonin and Its Metabolites in the Rat Brain Structures
In the hypothalamus, the two-way ANOVA revealed a
significant effect of 1MeTIQ (10 mg/kg i.p.) (F[1,19] =
58.3, P \ 0.01) on serotonin concentration (Table 3). In
opposite to this, the effect of desipramine (10 mg/kg i.p.)
(F[1,19] = 0.09, N.S.) or the 1MeTIQ versus desipramine
interaction was not significant (F[1,19] = 1.12, N.S.). The
Duncan’s post hoc test demonstrated that 1MeTIQ pro-
duced a significant elevation of serotonin concentration (by
about 25 %, P \ 0.01) in both treatment groups in the
hypothalamus (Table 3). The two-way ANOVA indicated a
significant effect of 1MeTIQ (F[1,19] = 4.62, P \ 0.05)
on the level of 5-HIAA in the hypothalamus (Table 3).
The same statistical analysis showed that the effect of
desipramine (F[1,19] = 0.51, N.S.) or 1MeTIQ and desi-
pramine interaction on the regulation of 5-HIAA concen-
tration (F[1,19] = 0.07, N.S.) were not significant
(Table 3).
Fig. 4 The effect of 1MeTIQ compared with desipramine as well as
combined administration of both this drugs on the rate of release of
noradrenaline expressed as ([NMN]/[NA]) 9 100 in rat hypothala-
mus. The rats received a single injection of saline (control),
desipramine (10 mg/kg i.p.) or 1MeTIQ (10 mg/kg i.p.). In the
mixed group, 1MeTIQ was given 15 min before desipramine
injection. The rats were decapitated about 1 h after desipramine
administration, immediately after completion of a behavioral test
(FST). The results are expressed as the mean ± SEM from 4 to 6
samples. The indices were calculated using concentrations from
individual tissue samples. The data were analyzed by means of two-
way analysis of variance ANOVA, followed when appropriate, by
Duncan’s post hoc test. Statistical significance: * P \ 0.05,
** P \ 0.01 versus control group
Table 3 The influence of 1MeTIQ, desipramine, and combined
administration on serotonin and its metabolite concentration in rat
brain structures
Treatment 1 Treatment 2 5-HT (ng/g t) 5-HIAA (ng/g t)
Hypothalamus
Saline Saline 921 ± 27 530 ± 27
Desipramine 10 943 ± 25 553 ± 18
1MeTIQ 10 Saline 1,172 ± 17**## 485 ± 16
Desipramine 10 1,132 ± 26**## 496 ± 17
Effect of 1MeTIQ F(1/19) = 58.3 F(1/19) = 4.62
P \ 0.01 P \ 0.05




F(1/19) = 1.12 F(1/19) = 0.07
N.S. N.S.
Striatum
Saline Saline 454 ± 19 534 ± 26
Desipramine 10 487 ± 21 628 ± 35
1MeTIQ 10 Saline 393 ± 11*## 565 ± 9
Desipramine 10 499 ± 13 516 ± 31#
Effect of 1MeTIQ F(1/19) = 12.26 F(1/19) = 1.49
P \ 0.01 N.S.




F(1/19) = 3.5 F(1/19) = 4.61
N.S. P \ 0.05
1MeTIQ was administered once in a dose 10 mg/kg i.p. Desipramine
was administered in acute dose 10 mg/kg i.p. In the mixed group,
1MeTIQ was given 15 min before desipramine injection. Control
group was treated with saline. The rats were decapitated about 1 h
after desipramine administration, immediately after completion of a
behavioral test (FST). The results are expressed as the mean ± SEM
from 4 to 6 samples. The indices were calculated using concentrations
from individual tissue samples. The concentration of serotonin and its
metabolite was measured in ng/g tissue. The data were analyzed by
means of two-way analysis of variance ANOVA, followed when
appropriate, by Duncan’s post hoc test. Statistical significance:
* P \ 0.05, ** P \ 0.01 versus Control group; # P \ 0.05,
## P \ 0.01 versus desipramine-treated group
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In the striatum, a two-way ANOVA revealed a significant
effect of 1MeTIQ (F[1,19] = 12.26, P \ 0.01) on serotonin
concentration but the effect of desipramine (F[1,19] = 1.54,
N.S.) was not significant (Table 3). At the same time, the
interaction between 1MeTIQ versus desipramine was not
significant (F[1,19] = 3.5, N.S.). The statistical analysis
demonstrated no effect of 1MeTIQ (F[1,19] = 1.49, N.S.) or
desipramine (F[1,19] = 0.45, N.S.) on 5-HIAA concentra-
tion (Table 3). The two-way ANOVA indicated a significant
effect of 1MeTIQ versus desipramine interaction (F[1,19] =
4.61, P \ 0.05) on the level of 5-HIAA.
The Effect of 1MeTIQ, Desipramine, and Their Combined
Administration on the Rate of Serotonin Metabolism
in the Rat Hypothalamus
The statistical analysis demonstrated a significant effect of
1MeTIQ (F[1,19] = 44.2, P \ 0.01) on the rate of sero-
tonin metabolism in the hypothalamus (Fig. 5). In opposite
to this, the effect of desipramine (F[1,19] = 0.55, N.S.) or
the interaction between 1MeTIQ and desipramine (F[1,19] =
0.09, N.S.) was not significant (Fig. 5). The Duncan’s post
hoc test indicated that 1MeTIQ given alone and combined
with desipramine reduced the serotonin metabolism rate (by
about 30 %, P \0.01).
Discussion
The main finding of this paper is that the endogenous neu-
roprotective compound, 1MeTIQ administered systemically
to rats produced antidepressant-like effect in the FST. This
effect was intensified by combined administration of 1Me-
TIQ and desipramine, a classic tricyclic antidepressant.
Neurochemical data showed that this effect was connected
with the activation of all monoaminergic (dopaminergic,
serotoninergic, and noradrenergic) systems.
Desipramine is a well-known tricyclic antidepressant
which acts as a selective noradrenaline reuptake inhibitor
(Grunewald et al. 1979; Javaid et al. 1979; Wroblewski
et al. 1996). In rodents, desipramine induced a significant
decrease in the immobility time in the forced swimming
test (Redrobe et al. 1996; Lucki et al. 2001; Holmes 2003;
Kim et al. 2010) with simultaneous elevation of the
climbing time. The modified FST measures the frequency
of different types of active behaviors: swimming, which is
sensitive to serotoninergic compounds, such as SSRIs, and
climbing, which is sensitive to tricyclic antidepressants and
drugs with selective effects on catecholamine transmission
(Cryan and Lucki 2000; Cryan et al. 2005; Detke et al.
1995). As shown by Detke et al. (1995), the increase in
climbing activity is connected with an enhanced norad-
renergic system activation.
Our present data from the behavioral experiments
demonstrated that acute systemic administration of 1Me-
TIQ in a low dose (10 mg/kg i.p.) produced antidepressant-
like effect by reducing the immobility time (Fig. 1a) with
simultaneous elevation of the climbing time (Fig. 1c). This
effect was similar to the influence induced by desipramine
given in a lower dose (10 mg/kg i.p.) (Fig. 1a, c). The
higher dose of desipramine produced a stronger decrease in
the immobility time (Fig. 1a) with simultaneous powerful
elevation of the climbing time (Fig. 1c). In the combination
group, when 1MeTIQ was given together with a lower dose
of desipramine, the reduction of the immobility time was
slightly stronger than in the 1MeTIQ group with a signif-
icant increase in the swimming time (Fig. 1a, b). These
data coming from the behavioral FST suggest that 1MeTIQ
(given alone in a low dose), similarly to desipramine,
influences mainly the catecholaminergic system. In oppo-
site to this, when 1MeTIQ was administered in combina-
tion with desipramine, the activation of serotoninergic
system seemed to be the dominant which was reflected by
the swimming behavior in this group (Fig. 1b).
In our earlier studies, we demonstrated that 1MeTIQ
was a reversible, short-acting and moderate inhibitor of
both MAO-A and MAO-B activity (Antkiewicz-Michaluk
et al. 2001; Patsenka and Antkiewicz-Michaluk 2004).
There are evidences that MAO inhibitors have several
particularly useful therapeutic properties, such as the
blockade of the oxidation pathway (leading to reduced free
radical production) in monoamine catabolism (Youdim
et al. 2006) and the increase in the concentration of
monoamines in the brain by inhibition of their catabolism
Fig. 5 The effect of 1MeTIQ compared with desipramine as well as
combined administration of both this drugs on the rate of final
serotonin metabolism expressed as ([5-HIAA]/[5-HT]) 9 100 in rat
hypothalamus. The rats received a single injection of saline (control),
desipramine (10 mg/kg i.p.) or 1MeTIQ (10 mg/kg i.p.). In the mixed
group, 1MeTIQ was given 15 min before desipramine injection. The
rats were decapitated about 1 h after desipramine administration,
immediately after completion of a behavioral test (FST). The results
are expressed as the mean ± SEM from 4 to 6 samples. The indices
were calculated using concentrations from individual tissue samples.
The data were analyzed by means of two-way analysis of variance
ANOVA, followed when appropriate, by Duncan’s post hoc test.
Statistical significance: * P \ 0.05, ** P \ 0.01 versus control group
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(Alvarez et al. 1999; Haefely et al. 1992). This mechanism
of action is responsible not only for neuroprotective effects
but also for antidepressant-like activity of MAO inhibitors
(e.g., selegiline or moclobemide) in different animal
models (Cryan et al. 2005; Kitamura et al. 2008; Miura
et al. 1996; Youdim and Bakhle 2006). In order to exclude
the psychostimulating activity of 1MeTIQ, we have
examined the influence of its administration (alone and
combined with desipramine) on locomotor activity of rats.
1MeTIQ administered in a dose of 10 mg/kg i.p. or desi-
pramine (10 mg/kg i.p.) induced a significant decrease in
locomotor activity (Fig. 2). An even stronger reducing
effect on motility was observed in the combination group
(Fig. 2). These results clearly show that 1MeTIQ, like
desipramine, did not have psychostimulant properties and
the prolonged climbing or swimming time (in the combi-
nation group) in the forced swimming test was the result of
an increased motivation to escape from the stressful situ-
ation, i.e., placing the animal in the cylinder with water.
The results from behavioral experiments were confirmed
by the neurochemical data. For presentation the neuro-
chemical results we selected two brain structures: con-
nected with monoaminergic function: the striatum—as a
representative of the dopaminergic system and motor
function, and the hypothalamus for noradrenergic system.
It should be borne in mind that serotonin nerve endings are
present in large numbers in both analyzed brain structures.
Some authors demonstrated that striatal dopamine play an
important role in the pathophysiology of depression by
modulating emotional and motor symptoms (Byrum et al.
1999; Newberg et al. 2007; Rogers et al. 1998). Addi-
tionally, Amsterdam et al. (2012) suggested that greater
striatal dopamine transporter density may represent a
putative biomarker of depression. Also Shah et al. (1997)
reported a decrease in dopamine function in the striatum of
patients with major depression. Moreover, evidence from
animal and human studies showed that stressful life events
and the consequent hypothalamic–pituitary–adrenal (HPA)
axis hyperactivity are among the most potent factors of
depressive episodes (Swaab et al. 2005; Wang et al. 2010).
As demonstrated in Table 1, 1MeTIQ in contrast to desi-
pramine, significantly affected the dopaminergic system. It
produced a significant elevation (P \ 0.05) of the dopa-
mine concentration in the hypothalamus. Additionally,
1MeTIQ induced a significant reduction (P \ 0.01) in the
level of the interneuronal dopamine metabolite, DOPAC
with simultaneous elevation (P \ 0.01) of the concentra-
tion of extraneuronal dopamine metabolite, 3-MT
(Table 1). At the same time, the rate of dopamine oxidation
expressed as the [DOPAC]/[DA] ratio was significantly
(P \ 0.01) decreased (Fig. 3a), and the marker of dopa-
mine reuptake inhibition, i.e., the [3-MT]/[DOPAC] ratio
was strongly increased (P \ 0.01) (Fig. 3b). This is a very
important property of 1MeTIQ because it not only induced
elevation of the dopamine concentration in the synaptic
cleft but also by blocking the activity of MAO it caused the
reduction of free radical production in the dopaminergic
neurons (Antkiewicz-Michaluk et al. 2001; Patsenka and
Antkiewicz-Michaluk 2004). 1MeTIQ, as a moderate and
reversible inhibitor of MAO-A and MAO-B (Patsenka and
Antkiewicz-Michaluk 2004) seems to be safe and effective
in clinic what can be important from practical point of
view. The formation of free radicals leads to oxidative
stress. Oxidative stress is a universal mechanism of
inducing cell death (Dykens 1999). Maes et al. (2009)
postulated a new theory of depression, which was called
‘‘the inflammatory and neurodegenerative hypothesis of
depression’’ which suggests that the activation of inflam-
matory and oxidative stress pathways is the cause of
development of depression (Maes et al. 2008). 1MeTIQ
given concomitantly with desipramine produced a signifi-
cant elevation (P \ 0.01) of the concentration of dopamine
with simultaneous reduction of the DOPAC level
(P \ 0.05) (Table 1). In the combination group, we
observed a significant decrease in the rate of dopamine
oxidation pathway expressed as the [DOPAC]/[DA] ratio
of the magnitude similar to the 1MeTIQ group (Fig. 3a),
however, the marker of dopamine reuptake inhibition; i.e.,
the [3-MT]/[DOPAC] ratio elevated by 1MeTIQ returned
to control values in the combined treatment group
(Fig. 3b). Simultaneously, the rate of total dopamine
metabolism measured as the [HVA]/[DA] 9 100 ratio was
significantly (P \ 0.05) decreased (Fig. 3c).
Similarly to desipramine, 1MeTIQ did not influence the
level of noradrenaline but induced a significant (P \ 0.01)
elevation of the NMN concentration in the hypothalamus
(Table 2). As shown in Fig. 4, 1MeTIQ produced an
increase (P \ 0.01) in the rate of noradrenaline release
measured as [NMN]/[NA] 9 100 with the same effec-
tiveness like desipramine. However, in the frontal cortex,
1MeTIQ acted more strongly than desipramine and sig-
nificantly (P \ 0.01) increased the concentration of both,
noradrenaline and NMN (Table 2). This effects of 1MeTIQ
may be associated with its ability to inhibit the noradren-
aline reuptake process. Noradrenaline released into the
synaptic cleft is catabolized by COMT to NMN by the
process of methylation. The increased amount of NMN
indicates the elevated release of noradrenaline or the
inhibition its uptake into the neuron. 1MeTIQ given in
combination with desipramine produced a significant
increase in the concentration of noradrenaline (P \ 0.05)
and its direct metabolite, NMN (P \ 0.01) (Table 2). At
the same time, the rate of extraneuronal noradrenaline
catabolism expressed as [NMN]/[NA] 9 100 was strongly
elevated (more than in the groups treated with each drug
alone) (Fig. 4). The strongest activation of noradrenergic
332 Neurotox Res (2014) 25:323–334
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system was observed in the combined treatment group in
the hypothalamus where both, the concentration of nor-
adrenaline and its metabolite, NMN was significantly ele-
vated (Table 2).
The present data demonstrated that desipramine given in
a dose (10 mg/kg i.p.) did not affect the concentration of
serotonin and its metabolite, 5-HIAA (Table 3). Also the
rate of serotonin metabolism measured as [5-HIAA]/[5-
HT] 9 100 was not changed by desipramine (Fig. 5). In
contrast to desipramine, 1MeTIQ produced a significant
elevation (P \ 0.01) of the serotonin concentration in the
hypothalamus (Table 3). Additionally, the rate of serotonin
metabolism estimated as [5-HIAA]/[5-HT] 9 100 was
significantly (P \ 0.01) decreased in this group (Fig. 5).
The observed neurochemical changes in the serotoninergic
system are the result of the inhibition of MAO activity in
the rat brain by 1MeTIQ (Patsenka et al. 2004). The neu-
rochemical data demonstrated that in the hypothalamus, the
concentration of serotonin was significantly increased
(P \ 0.01) in the combined treatment group (Table 3).
Simultaneously, the rate of serotonin metabolism measured
as [5-HIAA]/[5-HT] 9 100 was significantly decreased
(P \ 0.01) in this group (Fig. 5).
Our present data demonstrate that 1MeTIQ is charac-
terized by a wide spectrum of actions on all monoamin-
ergic systems in the rat brain. Thanks to its ability to inhibit
both MAO-A and MAO-B activity (Patsenka and Ant-
kiewicz-Michaluk 2004) and to scavenge free radicals
(Antkiewicz-Michaluk et al. 2006); 1MeTIQ may be useful
not only for the therapy of neurodegenerative disease but
also in the treatment of depression.
Conclusion
In summary, we have found that 1MeTIQ an endogenous
neuroprotective compound, given alone and in combination
with desipramine, exhibited antidepressant-like activity in
the forced swimming test in the rat. The neurochemical
results presented in this paper strongly support this sug-
gestion. Antidepressant-like properties of 1MeTIQ are
associated with the activation of all monoaminergic sys-
tems in the brain mainly by MAO inhibition and free
radical scavenging properties. Owning to these mecha-
nisms of action, 1MeTIQ may be very beneficial from the
clinical point of view as a new antidepressant.
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